U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H28F2N6O4S
Molecular Weight 522.568
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TICAGRELOR

SMILES

CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC=C(F)C(F)=C5)=N1

InChI

InChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H28F2N6O4S
Molecular Weight 522.568
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500123240.pdf; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002303/WC500100562.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000PharmR.pdf

Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4, potential activators of CYP3A5 and inhibitors of the P-gp transporter. Most common adverse reactions are bleeding 12% and dyspnea 14%.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
BRILINTA

Approved Use

Indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

Launch Date

1.31112003E12
Secondary
BRILINTA

Approved Use

Indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

Launch Date

1.31112003E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1583 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1208 ng/mL
270 mg single, oral
dose: 270 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
1208 ng/mL
360 mg single, oral
dose: 360 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10160 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12379 ng*h/mL
270 mg single, oral
dose: 270 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
12381 ng*h/mL
360 mg single, oral
dose: 360 mg
route of administration: oral
experiment type: single
co-administered:
TICAGRELOR plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICAGRELOR plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1260 mg single, oral
Highest studied dose
healthy
n = 6
DLT: Gastrointestinal disorder NOS, Sinus arrest...
Dose limiting toxicities:
Gastrointestinal disorder NOS (50%)
Sinus arrest (serious, 16.7%)
High grade atrioventricular block (serious, 16.7%)
Ventricular escape rhythm (serious, 16.7%)
Sources:
900 mg single, oral
MTD
healthy
n = 6
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Co-administed with::
aspirin, p.o
Sources: Page: p.3
unhealthy
n = 9333
Health Status: unhealthy
Condition: acute coronary syndrome
Sex: M+F
Population Size: 9333
Sources: Page: p.3
Disc. AE: Dyspnea...
AEs leading to
discontinuation/dose reduction:
Dyspnea (0.9%)
Sources: Page: p.3
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: acute coronary syndrome
Sources: Page: p.1
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disorder NOS 50%
DLT
1260 mg single, oral
Highest studied dose
healthy
n = 6
High grade atrioventricular block serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
n = 6
Sinus arrest serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
n = 6
Ventricular escape rhythm serious, 16.7%
DLT
1260 mg single, oral
Highest studied dose
healthy
n = 6
Dyspnea 0.9%
Disc. AE
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Co-administed with::
aspirin, p.o
Sources: Page: p.3
unhealthy
n = 9333
Health Status: unhealthy
Condition: acute coronary syndrome
Sex: M+F
Population Size: 9333
Sources: Page: p.3
Bleeding grade 3-5
Disc. AE
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: acute coronary syndrome
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
likely
moderate [IC50 10.5 uM]
moderate [IC50 11.7 uM]
moderate [IC50 26.7 uM]
moderate [IC50 33 uM]
moderate [IC50 43 uM]
moderate [IC50 6.9 uM]
no (co-administration study)
Comment: Human liver microsomes, dicrofenac (substrate); Co-administration of ticagrelor (180 mg BID x 9 days) did not alter the systemic exposure of tolbutamide (500 mg QD on Day 5, CYP2C9 substrate) (GM ratio of AUCinf and Cmax were 103%, 110%, while 4-OH tolbutamide AUCinf GM ratio and Cmax GM ratio were 94% and 90%).
Page: 9-11
moderate [IC50 7.6 uM]
moderate [IC50 8.2 uM]
yes (co-administration study)
Comment: Human liver microsomes, midazolam (4-hydroxylation, substrate), no time-dependent inhibition; Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly increased simvastatin (80 mg on Day 5, CYP3A4/5 substrate) AUCinf by 56% and Cmax 81%, and simvastatin acid AUCinf by 52% and Cmax by 64%. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly reduced oral midazolam (7.5 mg AM on Days 1 & 7) AUCinf by 10%, and 4’-OH-midazolam by 42%. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day 1, 180 mg BID on Days 2-7) does not alter the systemic exposure of IV midazolam (2.5 mg IV over 2 min AM on Days 1 & 7) and significantly reduced 4’-OH- midazolam systemic exposure by ~ 23%.
Page: 9-12, 60-61, 66-67, (PMDA) 130
no [IC50 40 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
weak (co-administration study)
Comment: Human liver microsomes, midazolam (1-hydroxylation, substrate), midazolam 1-hydroxylation was activated in the presence of Cyt-b5 by 144.9% (CYP3A4 (cDNA expressed enzyme):Cyp-b5 = 1: 3 + 5.56 mcM ticagrelor), no time-dependent inhibition; Inhibited testosterone intrinsic clearance (IC50 = 23 mcM, pooled human liver microsomes (33 male and female donors); Co-administration of ticagrelor (270 mg AM + 90 mg PM on Day 1, 90 mg BID on Days 2-7) significantly increased atorvastatin (80 mg QD on Day 5) AUCinf 36% and Cmax 23%, atorvastatin lactone AUCinf 32% and Cmax 39%, s 2-OH atorvastatin AUCinf 33% and Cmax 13%, and 4-OH atorvastatin AUCinf 67% and Cmax 55%. Co-administration of ticagrelor (90 mg BID x 21 days) significantly increased ethinyl estradiol AUCinf, Cmax, and Cmin by 20%, 30.6%, and 20.2%, respectively. Co-administration of ticagrelor does not alter the systemic exposure of levonorgestrel. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day1, 180 mg BID on Days 2-7) significantly reduced oral midazolam (7.5 mg AM on Days 1 & 7) AUCinf by 10%, but did not alter 1’-OH- midazolam AUC. Co-administration of ticagrelor (270 mg AM + 180 mg PM on Day 1, 180 mg BID on Days 2-7) did not alter the systemic exposure of IV midazolam (2.5 mg IV over 2 min AM on Days 1 & 7) and 1’-OH-midazolam.
Page: 9-12, 62-63, 64-65, 66-67 (PMDA) 124-125, 130
no
no
no
no
no
no
no
no
strong [Ki 13.4 uM]
strong [Ki 16.3 uM]
strong [Ki 4.9 uM]
strong
weak
weak
yes [IC50 0.759 uM]
yes [IC50 1 uM]
yes [IC50 10 uM]
yes [IC50 16.9 uM]
yes [IC50 19.2 uM]
yes [IC50 19.9 uM]
yes [IC50 7.8 uM]
yes (co-administration study)
Comment: MDR1-MDCK monolayer, H3-digoxin (5 mcM) as a substrate, Flux ratio = 19.5 (digoxin only), 3.1 (digoxin + 10 mcM Ticagrelor); Co-administration of ticagrelor (400 mg QD, Days 1-16) significantly increased digoxin (0.25 mg BID on Day 6, 0.25 mg QD on Days 7-14, P-gp substrate) AUC0-72, Css,max, and Css, min by 28%, 75% and 31%, respectively.
Page: 4-5, 58-59 (PMDA) 157
yes [IC50 9.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 11 uM]
yes (co-administration study)
Comment: Human liver microsomes (determination of CYPs) and human cDNA expressed emzymes (Km for AR-C124910XX formation), Km (AR-C124910XX, human liver microsomes) = 27 mcM; Km (AR-C133913XX formation) = 41 mcM; Co-administration of ketoconazole (200 mg BID for 10 days, CYP3A4 inhibitor) significantly increased ticagrelor (90 mg QD on Day 4) AUCinf by 7.32 fold and Cmax by 2.35 fold, and decreased AR-C124910XX AUCinf by 56% and Cmax by 89%. Co-administration of diltiazem (240 mg QD x 14 days, moderate CYP3A4 inhibitor) significantly increased ticagrelor (90 mg QD on Day 8) AUCinf by 2.74 fold and Cmax by 1.69, and decreased AR-C124910XX AUCinf by 13% and Cmax by 38%. Co-administration of rifampin (600 mg QD Days 4-17, strong CYP3A4/P-gp inducer) significantly decreased ticagrelor (180 mg QD Days 1 & 15) AUCinf by 86% and Cmax by 73%, and decreased AR-C124910XX AUCinf by 46% and did not affect Cmax.
Page: 123, (ClinPharm) 5-6, 43-44, 45-47, 47-49
no
no
no
no
no
no
yes [Km 5.36 uM]
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Clinical overview of promising nonthienopyridine antiplatelet agents.
2008 Aug
Pharmacology of emerging novel platelet inhibitors.
2008 Aug
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
2008 Dec
Antiplatelet therapy in acute coronary syndromes.
2008 Jul
Gateways to clinical trials.
2008 Mar
Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease.
2008 Sep-Oct
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
2009 Apr
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
2009 Apr
AZD6140 and bleeding: towards safer antiplatelet therapy?
2009 Apr
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
2009 Apr
Test before you stop.
2009 Aug
[Anticoagulants of primary haemostasis].
2009 Aug
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
2009 Aug
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
2009 Aug
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
2009 Dec
Ticagrelor versus clopidogrel in acute coronary syndromes.
2009 Dec 10
Ticagrelor versus clopidogrel in acute coronary syndromes.
2009 Dec 10
Ticagrelor versus clopidogrel in acute coronary syndromes.
2009 Dec 10
ACP Journal Club. Ticagrelor was more effective than clopidogrel, with no increase in major bleeding in acute coronary syndromes.
2009 Dec 15
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
2009 Dec 22
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
2009 Feb
Advances in antiplatelet therapy: agents in clinical development.
2009 Feb 2
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
2009 Jan
New P2Y12 blockers.
2009 Jul
Future of oral antiplatelet therapy: four challenged hypotheses.
2009 Jun
Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model.
2009 Mar
Update on oral antiplatelet therapy: principles, problems and promises.
2009 May
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
2009 May
New antiplatelet drugs: beyond aspirin and clopidogrel.
2009 May
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
2009 Nov
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
2009 Sep
New P2Y12 antagonists.
2009 Sep
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
2009 Sep 10
Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond.
2009 Sep-Oct
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
2009 Winter
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
2010 Apr
[Update: oral platelet inhibitors in cardiology].
2010 Apr
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
2010 Apr
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques.
2010 Apr 12
The year in cardiothoracic and vascular anesthesia: selected highlights from 2009.
2010 Feb
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
2010 Feb 1
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
2010 Jan
Recent advances in cardiology.
2010 Jan
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
2010 Jan
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
2010 Jan 23
PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes.
2010 Jul
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
2010 Jul
Examining biology and pharmacology-based hypotheses in the PLATO trial.
2010 Jul
The case for routine genotyping in dual-antiplatelet therapy.
2010 Jul 6
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
2010 Mar 16
Patents

Patents

Sample Use Guides

Initiate treatment with 180 mg (two 90 mg tablets) oral loading dose. Continue treatment with 90 mg twice daily.
Route of Administration: Oral
In human liver microsomes, ticagrelor inhibited midazolam 4-hydroxylation with an IC50 of 8.2 uM. Evaluated in fresh human hepatocytes at concentration up to 20 uM, ticagrelor was not an inducer of CYP1A2 or CYP3A4.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:32:34 UTC 2023
Edited
by admin
on Wed Jul 05 23:32:34 UTC 2023
Record UNII
GLH0314RVC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TICAGRELOR
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BRILINTA
Brand Name English
1,2-CYCLOPENTANEDIOL, 3-(7-(((1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL)AMINO)-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL)-5-(2-HYDROXYETHOXY)-, (1S,2S,3R,5S)-
Systematic Name English
AZD-6140
Code English
TICAGRELOR [MI]
Common Name English
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Systematic Name English
POSSIA
Brand Name English
TICAGRELOR [EMA EPAR]
Common Name English
Ticagrelor [WHO-DD]
Common Name English
TICAGRELOR [EP MONOGRAPH]
Common Name English
TICAGRELOR [USAN]
Common Name English
TICAGRELOR [ORANGE BOOK]
Common Name English
ticagrelor [INN]
Common Name English
TICAGRELOR [USP-RS]
Common Name English
TICAGRELOR [JAN]
Common Name English
TICAGRELOR [MART.]
Common Name English
AZD6140
Code English
BRILIQUE
Brand Name English
AR-C126532XX
Code English
TICAGRELOR [VANDF]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS POSSIA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
EMA ASSESSMENT REPORTS BRILIQUE (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
WHO-ATC B01AC24
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
EMA ASSESSMENT REPORTS POSSIA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
WHO-VATC QB01AC24
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
NCI_THESAURUS C80483
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
NDF-RT N0000182142
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
EMA ASSESSMENT REPORTS BRILIQUE (AUTHORIZED:ACUTE CORONARY SYNDROME)
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
LIVERTOX NBK548529
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
Code System Code Type Description
MERCK INDEX
M10853
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C76404
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
RS_ITEM_NUM
1667177
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
DRUG CENTRAL
4184
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
RXCUI
1116632
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY RxNorm
MESH
C503700
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
INN
8772
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
SMS_ID
100000115464
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
LACTMED
Ticagrelor
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
CAS
274693-27-5
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
NDF-RT
N0000182141
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
EPA CompTox
DTXSID901009337
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL398435
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
NDF-RT
N0000190482
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY Phenylalanine Hydroxylase Activators [MoA]
PUBCHEM
9871419
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
HSDB
8306
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
NDF-RT
N0000182143
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY P2Y12 Receptor Antagonists [MoA]
CHEBI
68558
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
WIKIPEDIA
Ticagrelor
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
DRUG BANK
DB08816
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
USAN
TT-94
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
EVMPD
SUB30898
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
FDA UNII
GLH0314RVC
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
IUPHAR
1765
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
NDF-RT
N0000190115
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY Cytochrome P450 3A5 Inhibitors [MoA]
DAILYMED
GLH0314RVC
Created by admin on Wed Jul 05 23:32:35 UTC 2023 , Edited by admin on Wed Jul 05 23:32:35 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
INHIBITOR -> TARGET
METABOLIC ENZYME -> INHIBITOR
WEAK
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
SOLVATE->ANHYDROUS
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC